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CORRESPONDENCE
countries that can define their priorities
convincingly (but do not have large
populations of poor people), funding
for corrupt and dictatorial governments
that have little regard for their poorest
citizens, and the enormous waste of 
the limited talents of many developing
countries that have been spent 
on inventing new approaches to
developing competitive proposals to
satisfy yet another under-resourced aid
bureaucracy with little chance of
success.
That Périn and Attaran are urging a
repeat of the failed design for the
Global Fund that Attaran proposed in
his and Sach’s 2001 Lancet article2 as
the basis for allocating donor support
for the health sector as a whole, is
shameful. If there was ever a need 
for evidence-based thinking about
international health policy to replace
ideological befuddlement, Périn and
Attaran have demonstrated it in their
Viewpoint.
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with a public health-care budget of
about US$10 per person and real
allocation often being only half of this
amount,2 a system that emphasises
specialist centres, long multi-drug
treatments, and frequent and long
hospital stays cannot be maintained.3
An oversized and underpaid medical
corps (a doctor’s salary is about
US$15–30 per month) requires under-
the-table payments before any services
are provided.4 Protocols updated at
central level do not easily lead to better
quality of care, more user-friendly
services, more respect of patients’ rights,
or more rational drug use, because the
usual, donor-funded training courses are
insufficient to change a 7-decades-old
medical tradition.
Most health professionals would like
to rebuild the old system, and requests
to humanitarian organisations continue
to focus on renovation of buildings and
donation of drugs and equipment, with
little concern for the actual accessibility,
quality, and cost-efficiency of services
provided. Armenia’s recent HIV/AIDS
proposal to the Global Fund for AIDS,
Tuberculosis, and Malaria was fairly
well written thanks to input from
United Nations consultants. However,
no proposal has yet been submitted for
tuberculosis despite its being arguably a
much bigger public-health problem;
and care for sexually transmitted
infections, a key issue in HIV
prevention in this context, was largely
neglected.
Périn and Attaran’s model of dialogue
is being tested in the Global Fund, but
the application mechanism guarantees
neither that proposals are made bottom-
up, nor that priority problems are
tackled.
What I understand by dialogue is an
engagement in practical work alongside
local counterparts to see if different
approaches can work in practice, to
understand the needs of the people, and
to ensure that those most in need benefit
from essential services. 
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Imatinib or transplant for
chronic myeloid leukaemia?
Sir—In his account of the development
of imatinib and its remarkable clinical
efficacy in chronic myeloid leukaemia,
Edward Sausville (April 26, p 1400)1
alludes to the dilemma that faces newly
diagnosed patients who in the pre-
imatinib era would have been obvious
candidates for early allogeneic stem-cell
transplantation. We agree with his view
that the long-term benefit of imatinib
cannot yet be reliably assessed, but 
feel he has perhaps underemphasised
the likelihood of cure in patients who,
for long periods after transplant, have
no evidence of residual disease even 
at the molecular level. Sausville draws
attention to the fact that stem-cell
transplants are hazardous, but omits
mention of the fact that reduced
intensity allografts are undoubtedly
safer and could be as good as
conventional transplants for treating the
disease.2,3
The decision not to offer selected
newly diagnosed patients the option of
an allograft as primary treatment is
probably simplistic. A good case can 
be made for identifying transplant
candidates by combining the use of the
Sokal or Hasford risk criteria to define 
a patient with standard or poor
prognosis with non-transplant therapy
with the Gratwohl score to identify a
patient with a good chance of survival
after transplant and consequently a
reasonably good chance of cure.4,5
In the next few years, improved
knowledge of overall survival data with
imatinib, improved understanding of 
the effect on survival of complete
cytogenetic responses to imatinib, and
updated assessment of reduced intensity
conditioning allografts should allow
more definite recommendations. In the
meantime, we believe that the younger
patient who is not low-risk and who 
has an HLA-identical sibling or a
molecularly HLA-matched unrelated
donor should still be offered the choice
of an initial trial of imatinib or an up-
front transplant. 
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Sir—Ines Périn and Amir Attaran1 want
to replace ideology with dialogue in
international medical aid. But by basing
donor funding exclusively on a recipient
country’s proposals they assume that
governments of such countries always
act in the best interests of the
populations they represent. However, in
many countries people suffer exactly
because of the negligence, corruption,
and unfair policies of their governments. 
Périn and Attaran suggest that
submitted proposals should be assessed
only if they are technically sound and
fiscally accountable. This way of
thinking presents exactly the same
problems as the World Bank’s
conditional loans policies they criticise.
The negative examples they cite
represent countries where populations
suffer because of irrational medical
policies; precisely the reason why
medical aid is so essential. The most
acute needs are usually noted among
populations under irresponsible
governments.
Few will disagree that dialogue is
necessary, but discussions need to
involve more than assessment of
recipient proposals. In Armenia, health
professionals look with great pride at the
Soviet health-care system. However,
